The FDA has approved Janssen's blood thinner Xarelto to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease.
Paratek has received the FDA's nod for Nuzyra for community-acquired bacterial pneumonia and acute skin and skin structure infections, as well as Seysera for acne.